{"id":11064,"date":"2025-07-15T14:30:00","date_gmt":"2025-07-15T06:30:00","guid":{"rendered":"https:\/\/credevo.com\/articles\/?p=11064"},"modified":"2025-08-23T18:35:41","modified_gmt":"2025-08-23T10:35:41","slug":"dcgi-approval-in-india-a-complete-guide-to-drug-regulations-clinical-trials-patient-safety","status":"publish","type":"post","link":"https:\/\/credevo.com\/articles\/2025\/07\/15\/dcgi-approval-in-india-a-complete-guide-to-drug-regulations-clinical-trials-patient-safety\/","title":{"rendered":"DCGI Approval In India: A Complete Guide To Drug Regulations, Clinical Trials, & Patient Safety"},"content":{"rendered":"\n

The Drugs Controller General of India (DCGI) heads the Central Drugs Standard Control Organization (CDSCO), overseeing DCGI approval in India, regulation, and quality standards of drugs and clinical trials. As the national regulatory authority, DCGI ensures patient safety and compliance with the Drugs and Cosmetics Act, 1940.<\/p>\n\n\n\n

\"DCGI<\/figure>\n\n\n\n

DCGI in the Indian pharmaceutical and medical device industries is among the world’s most regulated, and rightly so. The products these businesses produce have a direct and significant impact on the public’s health. In India, the ultimate authority in this area is the Drug Controller General of India (DCGI), whose job is to ensure that all drugs, vaccines, and medical devices meet safe and effective national and international standards before they’re allowed to enter the marketplace.<\/p>\n\n\n\n

For any life sciences company (biotech, pharmaceutical manufacturing industry) that operates in or sells to the burgeoning Indian pharmaceutical market, understanding the DCGI’s role, rules, and procedures is a matter of regulatory necessity. However, even more so, it’s a governance pathway to innovation and growth for the Indian and the global pharmaceutical sector.<\/p>\n\n\n\n

In this article, we cover the role and importance of DCGI, approval timelines and fees, regulatory framework under NDCT Rules, stepwise approval pathways, ongoing processes, annual approval trends, global acceptance of DCGI studies, and the future outlook of India\u2019s regulatory landscape.<\/p>\n\n\n\n

1. Work, approval timeline, and fees<\/h2>\n\n\n\n

The work of the DCGI is a meticulous, multi-stage process designed to thoroughly vet a product before it is approved. The journey begins with the submission of an application through the online SUGAM <\/a>portal, a centralized system for all regulatory submissions. The application and approval process for a new drug is governed primarily by the New Drugs and Clinical Trials (NDCT) Rules, 2019<\/a>. This pathway involves a series of steps, each with its own timeline and associated fees. For a new drug, the application is submitted using a specific form (Form 44). The fees are substantial:<\/p>\n\n\n\n

Step\/Activity<\/th>Fee (INR)<\/strong><\/th><\/tr><\/thead>
Pre-submission meeting<\/td>500,000<\/td><\/tr>
Post-submission meeting<\/td>50,000<\/td><\/tr>
Application for manufacturing a new drug\/IND for a CT or BA\/BE study<\/td>5,000 per product<\/td><\/tr>
Reconsideration of application for Manufacturing New Drug\/IND for CT or BA\/BE study<\/td>2,000 per product<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The approval timeline for a new drug can vary depending on various factors or conditions. While some stages can be completed within 90 days, full market approval usually takes 12\u201318 months.
This depends on the completeness and quality of the submitted data. It also varies if regulators request clarifications.<\/p>\n\n\n\n

2. Rules and regulations<\/h2>\n\n\n\n

The regulatory framework for drugs and clinical trials in India has evolved significantly to improve the standard and quality. The cornerstone of the current system is the New Drugs and Clinical Trials (NDCT) Rules, 2019<\/strong>, which replaced the older, more complex system under the Drugs and Cosmetics Act, 1940, and its Schedule Y. These rules provide a clear, detailed, and streamlined framework for the entire approval process currently in place.<\/p>\n\n\n\n

Key aspects of the NDCT Rules, 2019, include<\/strong><\/p>\n\n\n\n